Psychiatric disorders, like major depressive disorder, are influenced by multiple genes, revealing a notable genetic overlap with other conditions. This challenges our understanding of these disorders.
In this video with Dr. Jasmina Mallet highlights the latest research in psychiatric genetics, emphasizing the role of Polygenic Risk Scores (PRS) in psychiatry and their clinical applications.
Related content
This slide deck summarizes the current knowledge surrounding the use of psychedelics for the treatment of depression. Specifically, our focus centers on serotonergic psychedelics, commonly referred to as classical psychedelics. These psychedelics primarily function as agonists or partial agonists at the serotonin 2A receptor (5-HT2A receptor).
The infographic shows a 27% increase in depression cases due to COVID-19, affecting 280 million people worldwide.
This article discusses the latest advances in psychiatric genetics, focusing on MDD, the use of PRS in research, and potential future clinical practice applications.